Merck researcher hints that company may again sell Vioxx

Share this article:
Merck said yesterday it would consider returning Vioxx to the market if an FDA advisory committee decides the drug's risks are also found in other similar medicines.
Merck research head Peter Kim said, "If the advisory committee and the FDA conclude that the benefits of this class outweigh the risks in some patient populations, then we would have to consider the implications of these new data, given the unique benefits Vioxx offers," according to a Wall Street Journal report.
Kim made the comments to an FDA advisory panel during the second of three days of deliberations on the safety of painkilling drugs. The panel is due to vote later today.
A reversal of the withdrawal would be a shocking turn of events after one of the biggest drug withdrawals in U.S. history.
Merck offered its thoughts as members of the advisory committee were coming to an apparent consensus that signs of cardiovascular risk were not limited to Vioxx and likely applied to other COX-2s such as Pfizer's Bextra and Celebrex.
Meanwhile, European regulators yesterday took their own action against COX-2s concluding drugs in the class carry increased cardiovascular risks and imposing stronger warning labels on all of the drugs.
Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.